1. Global Portfolio of Antimalarial Medicines
Research
Translational
Product development
Access
Lead
optimization
Human volunteers
Patient exploratory
Patient confirmatory
Regulatory review
Preclinical
Post approval
DHODH
UTSW/UW/Monash
1 project
Novartis
P218
(Biotec)
MMV048
UCT/TIA
OZ439/PQP
Sanofi
Tafenoquine
GSK
Rectal Artesunate *
Cipla/Strides/WHO-TDR
Artemether-
lumefantrine
Dispersible
Novartis 1
Open Source Drug Discovery
Univ. Sydney
2 projects
GSK
SJ733
St Jude/Eisai
ACT840
Actelion
OZ439/FQ
Sanofi
Dihydroartemisinin piperaquine
Paediatric
Sigma-Tau
Arterolane/PQP
Ranbaxy * *
Artesunate
for injection
Guilin 2
Heterocycles
UCT
Orthologue Leads
Sanofi
DDD498
Merck Serono
(Univ. Dundee)
CDRI 9778
Ipca
Dihydro-artemisinin- piperaquine
Sigma-Tau
KAE609
Novartis
Co-trimoxazole
ITM Antwerp 3
Diversity Oriented
Synthesis
Broad/Eisai
Tetraoxanes
LSTM/Liverpool
PA92
(Drexel/UW/GNF)
N tert butyl
Isoquine
LSTM/Liverpool/GSK
Artemisinin
Naphthoquine * *
KPC
Pyronaridine-
artesunate
Shin Poong
KAF156
Novartis 4
dUTPase
Inhibitors
Medivir
Whole cell
St Jude/Rutgers/USF
MMV253
(AstraZeneca)
Artemether sub-lingual spray
PhotoPharma Ltd
Artesunate-
amodiaquine *
Sanofi/ DNDi
DSM265
Takeda 5
Imidazolidine
diones
WRAIR
Heterocycles
Celgene
GSK030
GSK
Artesunate-
Mefloquine *
Cipla/DNDi
Fosmidomycin Piperaquine
Jomaa Pharma/GmbH
Pf NDH2
Imperial College
London
Pf NMT
Imperial College
London
DSM421
(UTSW/UW/
Monash)
Methylene Blue/AQ
Heidelberg
SPAQ *
Guilin 6
Pantothenamides
TropIQ/Pansynt
TI Pharma
AN13762
Anacor
SAR97276
Sanofi
Pyronaridine-
Artesunate Paediatric
Shin Poong
NPC1161B
Mississippi
Artemisone
UHKST
JPC2997
Jacobus
AQ13
Immtech
MK4815
Merck
DF02
Dilafor
Footnotes: Brand names 1: Coartem® Dispersible; 2: Artesun®; 3: Euratesim®; 4: Pyramax®; 5: CoarsucamTM ASAQ/Winthrop®;
6: SPAQ-COTM

2. Description Target Product Profiles and Target Candidate Profiles:
The malaria community has defined two Target Product Profiles (TPPs) for medicines to make eradication achievable: TPP1: a treatment combination that is ideally a Single Exposure Radical cure and Prophylaxis (SERCaP) and TPP2: Single Exposure Chemoprotection (SEC).
3 day treatment products – TPP1
❯ Artemether-lumefantrine dispersible (Coartem® Dispersible), generic by Ajanta
❯ Dihydroartemisinin-piperaquine (Eurartesim®)
❯ Dihydroartemisinin-piperaquine paediatric (Eurartesim®)
❯ Pyronaridine-artesunate (Pyramax®)
❯ Pyronaridine-artesunate paediatric (Pyramax®)
❯ Artesunate-amodiaquine (CoarsucamTM, ASAQ/Winthrop®) FDC generics by Ajanta,
Ipca, Guilin and co-blistered generics by Strides & Cipla
❯ Artesunate-mefloquine, co-blistered generic by Acino/Mepha
New compounds to contribute to SERCAP or MERCAP (Multiple exposure radical cure prophylaxis) – TPP1
Seasonal malaria chemoprevention
❯ Sulfadoxine-pyrimethamine + amodiaquine (SP+AQ)
Severe malaria
❯ Rectal artesunate
❯ Artesunate for injection (Artesun®)
Relapse prevention
❯ Tafenoquine
To develop the individual compounds for combination into the TPPs,
MMV has defined five Target Candidate Profiles (TCPs):
Asexual blood stage activity (TCP1,2)
Relapse prevention (TCP3a)
Transmission reduction (gametocytocidal or sporontocidal) (TCP3b)
Chemoprevention (TCP4)
Brought into portfolio after approval. Collaboration with DNDi
No progress report in the last two years
Pending review or approval by WHO Prequalification, or by regulatory bodies who are ICH members or observers
Approved in several countries but not approved by SRA nor WHO prequal *
* *